title: Successful ceritinib treatment in a man with MPE and an ALK fusion gene mutation after multiple treatments.
abstract: BACKGROUND
  Ceritinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor. It inhibits two of the most common ALK-mutants that confer resistance to crizotinib. Ceritinib was approved by Food and Drug Administration in April 2014. However, the efficacy of ceritinib in Asian patients have not been widely studied. Decrease of malignant pleural effusion (MPE) has been rarely reported after treatment with ceritinib.
  
  
  METHODS
  A 50-year old man diagnosed with stage IV lung adenocarcinoma presented with MPE and an ALK fusion gene mutation. The patient showed partial response to ceritinib after 2-month treatment. Ultrasound showed MPE significantly decreased.
  
  
  RESULTS
  Ceritinib is a good choice, as a targeted therapy, which is more prospect in the advanced cancer patients than the traditional therapy.
  
  
  CONCLUSIONS
  Ceritinib seems to have a good efficacy in reducing MPE in advanced Asian lung adenocarcinoma patients, when other chemotherapy failed.
authors.affiliation: Department of Medical Oncology, Dongyang People's Hospital, No. 60 West Wuning Road, Dongyang, 322100 Zhejiang People's Republic of China.
authors.forename: Hangping
authors.initials: H
authors.lastname: Wei
authors.affiliation: Department of Medical Oncology, Dongyang People's Hospital, No. 60 West Wuning Road, Dongyang, 322100 Zhejiang People's Republic of China.
authors.forename: Fangming
authors.initials: F
authors.lastname: Du
authors.affiliation: Department of Medical Oncology, Dongyang People's Hospital, No. 60 West Wuning Road, Dongyang, 322100 Zhejiang People's Republic of China.
authors.forename: Yifang
authors.initials: Y
authors.lastname: Lu
authors.affiliation: Department of Medical Oncology, Dongyang People's Hospital, No. 60 West Wuning Road, Dongyang, 322100 Zhejiang People's Republic of China.
authors.forename: Juan
authors.initials: J
authors.lastname: Wei
authors.affiliation: Department of Medical Oncology, Dongyang People's Hospital, No. 60 West Wuning Road, Dongyang, 322100 Zhejiang People's Republic of China.
authors.forename: Xiaofang
authors.identifier: 0000-0002-2904-7086
authors.initials: X
authors.lastname: Dong
keywords: ALK fusion gene mutation; Ceritinib; Lung adenocarcinoma; Malignant pleural effusion